title: [High-dose rate brachytherapy for high-risk prostate cancer].
abstract: To estimate disease-free survival it is necessary to allocate patients into tumor risk groups: locally advanced prostate carcinoma with extracapsular spread or localized prostate carcinoma of tumor stage T2c or one of the risk factors PSA >20 or Gleason > or =8 apply for the high-risk group. Intermediate-risk carcinomas are those belonging to tumor stage T2b or with PSA >10-20 or Gleason 7. Particularly for patients with intermediate and high-risk disease early PSA relapse is of major interest. This phenomenon could be a consequence of current inadequate imaging of lymph node or bone metastasis or as a consequence subclinical metastatic spread remains undetectable during radical treatment. However, tumor biology itself could lead to the progression of the disease in the high-risk group. As a consequence, risk-adapted therapy is very important in these cases. The applied radiation dose plays an important role in radiotherapy. Several publications have shown that the biochemical relapse correlates with the generally accepted risk factors and the radiation dose. Regarding this, high-quality treatment planning and HDR brachytherapy combined with EBRT (external beam radiation therapy) leads to good treatment results in selected groups. So far in our own experience, HDR brachytherapy in combination with EBRT is a successful form of treatment with few acute and late side effects in the first 42 patients examined. First results concerning to PSA relapse-free time, quality of life, miction, and erectile function are promising.
authors.affiliation: Urologische Klinik und Poliklinik, Universitätsklinikum, Hufelandstrasse 55, 45122, Essen. marcus.schenck@uni-essen.de
authors.forename: M
authors.initials: M
authors.lastname: Schenck
authors.forename: K
authors.initials: K
authors.lastname: Krause
authors.forename: R
authors.initials: R
authors.lastname: Schwandtner
authors.forename: I
authors.initials: I
authors.lastname: Haase
authors.forename: D
authors.initials: D
authors.lastname: Fluehs
authors.forename: J
authors.initials: J
authors.lastname: Friedrich
authors.forename: T
authors.initials: T
authors.lastname: Jaeger
authors.forename: C
authors.initials: C
authors.lastname: Boergermann
authors.forename: H
authors.initials: H
authors.lastname: Ruebben
authors.forename: M
authors.initials: M
authors.lastname: Stuschke
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D001918:Brachytherapy / Q000379:methods*; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D019160:Endosonography; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011788:Quality of Life; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D012306:Risk
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen